AGTR2 and pulmonary fibrosis: To our knowledge, this is the first report to show that stimulation of the AT2 receptor using a synthetic activator (C21) renders protection against bleomycin-induced cardiopulmonary injury, which could open up novel therapeutic avenues to tackle lung fibrosis and Group III PH.